TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26094549
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate gel (two‐compound gel) applied once daily
Study: 26094549
Drug: Calcipotriol scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol scalp solution applied twice daily
Study: 26094549
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate gel (two‐compound gel)
Study: 19286847
Drug: Febuxostat 120
Normalized name: Febuxostat 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 120 mg
Study: 1612362
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 2000 mg daily for 30 days
Study: 1612362
Drug: Calcium 2000
Normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 2000 mg daily for 4 weeks
Study: 28289280
Drug: l‐methylfolate 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐methylfolate 15 mg
Study: 24258313
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (IT) with cyproterone acetate (CPA) 100 mg tid
Study: 24258313
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment (CT) with cyproterone acetate (CPA) 100 mg tid
Study: 18931625
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (IT)
Study: 24258313
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (IT) and Continuous treatment (CT)
Study: 16002451
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) administration (7.5 IU or 2.5 mg)
Study: 31321800
Drug: 1,540 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,540 nm fractional erbium-glass laser therapy plus topical minoxidil solution applied twice daily for 6 weeks
Study: 31321800
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil solution only
Study: 30646142
Drug: Long-term nicotine
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term nicotine replacement therapy (LT-NRT) for 12 months with 6 follow-up counseling sessions
Study: 30646142
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation (SSC) treatment for 10 weeks with 4 follow-up counseling sessions
Study: 24715706
Drug: ACE-536 (0.0625-0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-536 (0.0625-0.25 mg/kg)
Study: 24715706
Drug: ACE-536 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-536 (0.25 mg/kg)
Study: 19443133
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list for methadone treatment
Study: 1916869
Drug: Two-hour infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-hour infusion of amphotericin B
Study: 1916869
Drug: Four-hour infusion
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-hour infusion of amphotericin B
Study: 7044099
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (cyclophosphamide, methotrexate, and 5‐fluorouracil)
Study: 30865794
Drug: 1-month regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month regimen of daily rifapentine plus isoniazid
Study: 22042247
Drug: 250-μg SS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-μg SS (scarification of the skin)
Study: 9811072
Drug: Higher inspired
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher inspired oxygen (0.25 L/min higher than baseline, SaO2 >97%)
Study: 2523644
Drug: Isradipine (once-daily)
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine (once-daily)
Study: 2523644
Drug: Isradipine (twice-daily)
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine (twice-daily)
Study: 7340890
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg once daily
Study: 506802
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg and 200 mg)
Study: 15723894
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise therapy
Study: 19704401
Drug: Limited sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited sampling strategies (LSS) for estimation of mycophenolic acid (MPA) AUC(0-12) after EC-MPS administration
Study: 17972276
Drug: High-dose glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose glycine (0.8 g/kg)
Study: 24061557
Drug: Low-carbohydrate (L-CHO)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate (L-CHO) diet
Study: 9291244
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and aspirin (current antithrombotic management)
Study: 7706179
Drug: Aspoxicillin 4
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspoxicillin 4 g tds (n = 52)
Study: 7706179
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g qds (n = 53)
Study: 3110654
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (600 mg per diem b.i.d.)
Study: 3110654
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (1800 mg per diem b.i.d.)
Study: 18299305
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza vaccine, trivalent, administered intranasally, 2 doses, 35 +/- 7 days apart.
Study: 18299305
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intranasally, 2 doses, 35 +/- 7 days apart.
Study: 3888864
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 400 mg thrice daily for 30 days
Study: 3888864
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg thrice daily for 30 days
Study: 20545388
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with CM-MEDICATION condition
Study: 15951873
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg daily for 12 weeks)
Study: 373105
Drug: Pirenzepine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (75 mg/day)
Study: 6096154
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/day)
Study: 20930643
Drug: PEG‐IFNα‐2b plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα‐2b plus ribavirin therapy continued post-seizure
Study: 16704650
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 5 mg daily
Study: 9728526
Drug: Valaciclovir 250
Normalized name: valacyclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 250 mg once daily
Study: 9728526
Drug: Valaciclovir 1
Normalized name: valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir 1 g once daily
Study: 18192785
Drug: Valaciclovir 250
Normalized name: valacyclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 250 mg twice daily
Study: 15571711
Drug: Comprehensive, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive, intensive treatment from 3 to 12 months post-stroke
Study: 28096757
Drug: PWS (pre-workout
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWS (pre-workout dietary supplement)
Study: 28096758
Drug: PWS +
Normalized name: Pulsed Wave Stimulation Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWS + S (pre-workout dietary supplement with p-synephrine)
Study: 20441061
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg TDS) until the end of 8 weeks gestation (Group B)
Study: 20441061
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg TDS) stopped immediately after diagnosis of pregnancy (Group A)
Study: 17022766
Drug: Oral nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nystatin prophylaxis administered three times a day to all neonates (Group B)
Study: 17022766
Drug: Oral nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nystatin prophylaxis for yeast carriers (Group A1)
Study: 10947033
Drug: Slow-release caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release caffeine 150 mg
Study: 29251282
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor antagonist amisulpride
Study: 21904194
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL sterile water intrathecally
Study: 21904194
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (200 μg) nalbuphine intrathecally
Study: 21904194
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (400 μg) nalbuphine intrathecally
Study: 18982918
Drug: Alendronate (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (once-weekly regimen)
Study: 8901155
Drug: Test patch
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test patch (Dermestril)
Study: 1746424
Drug: Pravastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 40 mg/day
Study: 7048879
Drug: Pindolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (mean dose 28 +/- 5 mg twice a day)
Study: 7048879
Drug: Methyldopa (673
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (673 +/- 158 mg three times a day)
Study: 30653147
Drug: Pre-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-administration of remifentanil before propofol infusion (Group R)
Study: 30653147
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of remifentanil with propofol (Group N)
Study: 30672195
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture therapy
Study: 30152573
Drug: Intranasal OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal OXT (24 IU)
Study: 22669143
Drug: Catuama (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catuama (herbal compound), 2 capsules each day for 8 weeks
Study: 10642289
Drug: Placebo CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo CPAP (administered at ineffective pressure)
Study: 3941567
Drug: Saphenous vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous vein grafts with aspirin and dipyridamole
Study: 29488276
Drug: Exenatide, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide, 5 μg BID for 30 days
Study: 29488276
Drug: Liraglutide, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide, 3 mg daily for 5 weeks
Study: 25141246
Drug: Ibuprofen/famotidine fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/famotidine fixed-dose tablet
Study: 12785122
Drug: Equally single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equally single dosed drugs (ASA and PSE)
Study: 12785122
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 500 mg acetylsalicylic acid (ASA) and 30 mg pseudoephedrine (PSE)
Study: 8862260
Drug: rhuIFN-gamma with
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuIFN-gamma with thalidomide and conventional multidrug chemotherapy
Study: 8862260
Drug: rhuIFN-gamma without
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuIFN-gamma without concomitant chemotherapy
Study: 27106721
Drug: DHA+EPA treatment
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+EPA treatment (4 g/day for 15-18 months)
Study: 25518878
Drug: Proactive motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive motivational telephone outreach with eight weeks of nicotine replacement therapy and eight sessions of specialized telephone counseling over two months, followed by monthly maintenance counseling for four months.
Study: 20153158
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (4 microg, inhaled 6-9 times daily, with a night pause; dose reduced to 2 microg if side effects occurred)
Study: 31056710
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch alone
Study: 27052635
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) for 24 weeks (open-label phase)
Study: 25116690
Drug: Psychotherapy (Narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (Narrative Exposure Therapy)
Study: 20016870
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin plus amoxicillin‐clavulanate (Group A)
Study: 18585831
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine (PV) + Influenza vaccine (IV)
Study: 18585831
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (IV)
Study: 15606590
Drug: Vamin 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamin 18 infusion (500 mls) administered immediately after induction of anaesthesia
Study: 15606590
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Vamin 18 administered)
Study: 10434232
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate sterile solution (IV infusion)
Study: 7811160
Drug: Neuroleptic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic medication dose reduction
Study: 2349364
Drug: Oxazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (10 mg) three times daily for 4 days
Study: 2349364
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tianeptine and oxazepam
Study: 25870324
Drug: Typbar-TCV (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typbar-TCV (single dose)
Study: 25870324
Drug: Typbar (Vi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typbar (Vi polysaccharide, single dose)
Study: 25870324
Drug: Typbar-TCV (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typbar-TCV (single dose) in OLT
Study: 24059784
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for Substance abuse and Partner violence (I-StoP)
Study: 24059784
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment addressing substance use disorders (CBT-SUD+)
Study: 7637045
Drug: 2-drug solution
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2-drug solution (papaverine + phentolamine)
Study: 23223597
Drug: Single-dose tribendimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose tribendimidine
Study: 11009268
Drug: Pravastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin plus anti-hypertensive drugs
Study: 11009268
Drug: Hypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive agents and diet control alone
Study: 11009268
Drug: Antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agents (normolipidemia)
Study: 6175138
Drug: Pimozide treatment
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide treatment
Study: 24571703
Drug: Stannous-containing sodium
Normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stannous-containing sodium fluoride dentifrice (Oral-B(®) Pro-Expert Sensitive)
Study: 20221984
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (TA) injection (group B)
Study: 15637533
Drug: CCI-779 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCI-779 (25, 75, or 250 mg once weekly)
Study: 11802924
Drug: Valaciclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1000 mg once daily
Study: 11802924
Drug: Valaciclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1000 mg twice daily
Study: 10233315
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite (HDM) levels > 2 microgram/g of dust
Study: 10233315
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite (HDM) levels between 0.1 and 2 microgram/g of dust
Study: 10233315
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite (HDM) levels < 0.1 microgram/g of dust
Study: 2551242
Drug: CDDP solution
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP solution as usually used
Study: 30794314
Drug: Peanut patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut patch containing 250 μg of peanut protein (n=238)
Study: 19922256
Drug: Mud therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud therapy (topical gel prepared using Lake Urmia mud)
Study: 23141953
Drug: Cervical artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical artificial insemination (CAI): 3×10(9) spermatozoa/80 ml
Study: 23141953
Drug: Post-cervical artificial
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-cervical artificial insemination (post-CAI 1): 1.5×10(9) spermatozoa/40 ml
Study: 23141953
Drug: Post-cervical artificial
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-cervical artificial insemination (post-CAI 2): 1×10(9) spermatozoa/26 ml
Study: 9819168
Drug: Placebo (PL:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL: maltodextrin capsule)
Study: 8583101
Drug: 5-ASA (Claversal),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA (Claversal), 0.5 g b.i.d.
Study: 2642669
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate 750 mg daily
Study: 20297858
Drug: OROS® hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS® hydromorphone administered once daily for up to 52 weeks
Study: 11923558
Drug: Caffeine capsule
Normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsule (200 mg)
Study: 9459251
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (5 mg) with intraarticular bupivacaine (30 mL of 0.25%)
Study: 9459251
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (5 mg) with normal saline (30 mL)
Study: 9459251
Drug: Intraarticular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular bupivacaine (30 mL of 0.25%)
Study: 9459251
Drug: Intraarticular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular bupivacaine (30 mL of 0.25%) with intravenous morphine (5 mg)
Study: 14618054
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of curved and straight shaft catheters
Study: 10753829
Drug: PEG‐rHuMGDF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF (3 microg/kg, single bolus subcutaneous injection)
Study: 27341795
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of chemotherapy
Study: 27341795
Drug: Chemotherapy scheme
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy scheme
Study: 22907974
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus Docetaxel (Gemcitabine 900 mg/m² i.v. for 90 minutes on days 1 and 8, plus Docetaxel 100 mg/m² i.v. for 1 hour on day 8 of a 21-day cycle with lenograstim)
Study: 20081039
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg three times per day
Study: 18076806
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with concurrent radiotherapy
Study: 20113303
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behaviour Therapy (CBT)
Study: 10474848
Drug: No-therapy control
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-therapy control group
Study: 8942598
Drug: Univent tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Univent tube with bronchial blocker
Study: 9476039
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pyridostigmine